Mylan launches copy of Novartis cancer med; Merck, Quiagen fund Rwanda HPV vax program;

@FiercePharma: AZ decides to tear down three HQ buildings. Story | Follow @FiercePharma

> Generic drugmaker Mylan has launched a copycat version of Novartis' breast cancer treatment Femara. Report

> Sinopharm, China's largest pharmaceutical products distributor, plans to issue H-shares to raise HK$3.4 billion ($440 million) to expand its retail network and working capital. Story

> Merck and Qiagen will fund a program in Rwanda to screen and vaccinate women against cervical cancer, the New Times reported, citing Agnes Binagwaho, permanent secretary in the Health Ministry. News

> Data on the effectiveness of Medicis Pharmaceutical's wrinkle-filler Restylane as a lip plumper may be unreliable, FDA reviewers said ahead of an advisory panel meeting to discuss the merits of the treatment. Item

> The FDA says Taro Pharmaceutical Industries can resume regular production at its Canadian manufacturing facility following a reinspection of the site in February. Article

> Hospira reported quarterly earnings above analysts' expectations as it benefited from the launch of cancer treatment docetaxel and several other compounds. News

> A study of Abbott Laboratories' Trilipix showed female patients who took the drug along with a statin experienced more heart problems than those on a statin alone, U.S. health regulators said. Report

> The Supreme Court has refused to consider an early challenge to the federal healthcare law, allowing an appeals courts to hear arguments first over the constitutionality of the Obama administration's signature legislative achievement. Item

> Pozen and AstraZeneca have sued India's Dr Reddy's Laboratories in a U.S. district court for alleged infringement of a patent related to the pain relieving drug Vimovo. Story

> India's Aventis Pharma, a unit of Sanofi-Aventis, reported a forecast-beating 40 percent rise in net profit for the quarter ended March 31, on higher sales and other income, pushing its shares up more than 10 percent. News

> China's Hebei Aoxing Pharmaceutical has passed a major milestone in its joint venture with process technology specialist Macfarlan Smith to make active pharmaceutical ingredients. Report

> Tablet testing tech specialist Sotax has set up a new unit in India in the first stage of a five-year plan to expand its business in the country. Article

> Vaccine specialist Caliber Biotherapeutics says it has opened the world's largest modular, plant-made pharmaceutical manufacturing facility at its headquarters in Bryan, Texas. Item

Biotech News

 @FierceBiotech: Pfizer scrambles to reassure investors on RA drug deaths. News | Follow @FierceBiotech

 @JohnCFierce: IMS/PhRMA will tell Supremes why they should continue to be allowed to use rx info for marketing. Free speech issue? Story | Follow @JohnCFierce

> Feds ramp up new efforts to spawn rare disease R&D. Report 

> VCs, Big Pharma join forces to tackle market challenges. Article

> Sequella inks $50M Russian licensing pact for TB treatment. Story 

Biotech Research News

> Study shows how methamphetamine destroys cells throughout the body. Article 

> Cardiac gene names get a heart-y laugh. Story

> New solution found for cystic fibrosis infections. Report 

Manufacturing News

> Solvent recovery takes sting out of carbon tax. Report 

> Genzyme hiring push a hopeful sign for industry. News 

> Merck hiring may show FDA influence. Story 

> Expert: FDA strategy document lacking in detail. Article 

> Cancer survivor makes jewelry from pills. News 

> Nader uses pharma to assail offshore outsourcing. Story

And Finally... HIV infections can increase the risk of heart failure even in patients who don't have a prior history of heart disease, a U.S. study said. Report

Suggested Articles

Bristol-Myers already has one Opdivo combo approved in kidney cancer, but it’s going for another—and new trial data could be just the ticket.

Trodelvy's bladder cancer data look weaker compared with what Seattle Genetics' rival drug Padcev achieved in its own trial.

Merck’s Keytruda is battling Bristol Myers' Opdivo in adjuvant melanoma, and it just racked up trial results that will help it even the playing field.